Embed Size (px)
Citation preview
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
NICE TAs 2020TA Subject Is the Technology Appraisal
relevant to Locala?If yes, does Locala comply with the
NICE Technology Appraisal?TA621 Osimertinib for untreated EGFR mutation-positive
non-small-cell lung cancer No
TA620 platinum-sensitive ovarian, fallopian tube or peritoneal cancer
No
TA619 receptor-positive, HER2-negative, advanced breast cancer
No
TA618 untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)
No
TA617 people with chronic liver disease needing a planned invasive procedure
No
NICE TAs 2019TA Subject Is the Technology Appraisal
relevant to Locala?If yes, does Locala comply with the
NICE Technology Appraisal?TA616 Cladribine for treating relapsing–remitting multiple
sclerosisNo
TA615 Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
No
TA614 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
No
TA613 chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy
No
TA612 receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
No
TA611 platinum-sensitive ovarian, fallopian tube or peritoneal cancer
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA610 Pentosan polysulfate sodium for treating bladder pain syndrome
No
TA609 hepatocellular carcinoma after sorafenib (terminated appraisal)
No
TA608 Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)
No
TA607 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Yes Yes
TA606 Lanadelumab for preventing recurrent attacks of hereditary angioedema
No
TA605 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
No
TA604 Idelalisib for treating refractory follicular lymphoma No
TA603 Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)
No
TA602 for treating relapsed or refractory multiple myeloma (terminated appraisal)
No
TA601 Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal)
No
TA600 untreated metastatic squamous non-small-cell lung cancer
No
TA599 Sodium zirconium cyclosilicate for treating hyperkalaemia
No
TA598 peritoneal cancer after response to first-line platinum-based chemotherapy
No
TA597 Dapagliflozin with insulin for treating type 1 diabetes No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA596 Risankizumab for treating moderate to severe plaque psoriasis
No
TA595 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
No
TA594 Brentuximab vedotin for untreated advanced Hodgkin lymphoma
No
TA593 receptor-positive, HER2-negative, advanced breast cancer
No
TA592 Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
No
TA591 Letermovir for preventing cytomegalovirus disease after a stem cell transplant
No
TA590 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
No
TA589 leukaemia in remission with minimal residual disease activity
No
TA588 Nusinersen for treating spinal muscular atrophy No
TA587 Lenalidomide plus dexamethasone for previously untreated multiple myeloma
No
TA586 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
No
TA585 Ocrelizumab for treating primary progressive multiple sclerosis
No
TA584 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
No
TA583 Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Yes Yes
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA582 Cabozantinib for previously treated advanced hepatocellular carcinoma
No
TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
No
TA580 Enzalutamide for hormone-relapsed non-metastatic prostate cancer
No
TA579 receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
No
TA578 unresectable non-small-cell lung cancer after platinum-based chemoradiation
No
TA577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
No
TA576 Bosutinib for untreated chronic myeloid leukaemia No
TA575 Tildrakizumab for treating moderate to severe plaque psoriasis
No
TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis
No
TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
No
TA572 Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Yes Yes
TA571 Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
No
TA570 squamous cell carcinoma of the head and neck after platinum-based chemotherapy
No
TA569 Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA568 Abatacept for treating psoriatic arthritis after DMARDs No
TA567 diffuse large B-cell lymphoma after 2 or more systemic therapies
No
TA566 Cochlear implants for children and adults with severe to profound deafness
No
TA565 Benralizumab for treating severe eosinophilic asthma No
TA564 metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)
No
TA563 negative, locally advanced or metastatic breast cancer
No
TA562 Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
No
TA561 Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
No
TA560 paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer
No
TA559 cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
No
TA558 resected melanoma with lymph node involvement or metastatic disease
No
TA557 chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
No
TA556 Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
No
TA555 Regorafenib for previously treated advanced hepatocellular carcinoma
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
NICE TAs 2018TA Subject Is the Technology Appraisal
relevant to Locala?If yes, does Locala comply with the
NICE Technology Appraisal?TA554 acute lymphoblastic leukaemia in people aged up to 25
yearsNo
TA553 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
No
TA552 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
No
TA551 Lenvatinib for untreated advanced hepatocellular carcinoma
No
TA550 Vandetanib for treating medullary thyroid cancer No
TA549 Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)
No
TA548 Decitabine for untreated acute myeloid leukaemia (terminated appraisal)
No
TA546 Padeliporfin for untreated localised prostate cancer No
TA545 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
No
TA543 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
No
TA542 Cabozantinib for untreated advanced renal cell carcinoma
No
TA541 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
Ta540 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
No
TA539 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
No
TA538 Dinutuximab beta for treating neuroblastoma No
TA537 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
No
TA536 Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
No
TA535 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
No
TA534 Beta interferons and glatiramer acetate for treating multiple sclerosis
No
TA533 Ocrelizumab for treating relapsing-remitting multiple sclerosis
No
TA532 Cenegermin for treating neurotrophic keratitis No
TA531 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell cancer
No
TA530 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
No
TA529 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA528 Niraparib for maintneance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
No
TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
No
TA522 Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
No
TA516 Cabozantinib for treating medullary thyroid cancer NoTA515 breast cancer after 1 chemotherapy regimen NoTA514 hepatocellular carcinoma NoTA513 lymphoma NoTA512 Tivozanib for treating advanced renal cell carcinoma NoTA511 psoriasis NoTA510 refractory multiple myeloma NoTA509 treating HER2-positive breast cancer NoTA508 cartilage defects of the knee NoTA507 chronic hepatitis C NoTA506 Lesinurad for treating chronic hyperuricaemia in
people with goutNo
TA505 treating relapsed or refractory multiple myeloma NoTA504 Pirfenidone for treating idiotic pulmonary fibrosis NoTA503 metastatic oestrogen-receptor positive breast cancer NoTA502 Ibrutinib for treating relapsed or refractory mantle cell
lymphomaNo
TA501 Intrabeam radiotherapy system for adjuvant treatment of early breast cancer
NoTA500 C eritinib for untreated ALK-positive non-small-cell lung
cancerNo
TA499 Glecaprevir–pibrentasvir for treating chronic hepatitis C
NoTA498 Lenvatinib with everolimus for previously treated
advanced renal cell carcinomaNo
TA497 spondyloarthritis No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA Subject Is the recommendation in the TA applicable to organization?
Does Locala comply with the NICE Technology Appraisal?
TA492 Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
No
TA491 Ibrutinib for treating Waldenstrom’s macroglobulinaemia
No
TA490 Nivolumab for treat squamous cell carcinoma of the head and neck after platinum-based chemotherapy
No
TA489 Vismodegib for treating basal cell carcinoma No
TA488 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
No
TA487 Venetoclax for treating chronic lymphocytic leukaemia
No
TA486 Afibercept for treating choroidal neovascularization No
TA485 Sarilumab for moderate to severe rheumatoid arthritis
No
TA484 Nivolumab for previously treated non-squamous non-small-cell lung cancer
No
TA483 Nivolumab for previously treated squamous non-small-cell lung cancer
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA480 Tocacitinib for moderate to severe rheumatoid arthritis
No
TA479 Reslizumab for treating sever eosinophilic asthma No
TA478 Brentuximab vedotin for treating relapsed or refractory system anaplastic large cell lymphoma
No
TA477 Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee)
No
TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
No
TA458 Tratuzumab emtabsine for treating HER2-postive advanced breast cancer after trastuzumab and a taxane
No
ID579 Psoriatic arthritis - certolizumab pegol and secukinumab (after DMARDs)
No
ID1017 Apremilast for treating active psoriatic arthritis No
TA431 Asthma (eosinophilic, severe) - mepolizumab No
TA430 Sofosbuvir–velpatasvir for treating chronic hepatitis C No
TA429 Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA428 Pembrolizumab for treating PD-L1-positive non-small- cell lung cancer after chemotherapy
No
TA427 Multiple myeloma (relapsed, refractory) - pomalidomide (after lenalidomide and bortezomib)
No
NICE TAs 2016TA Subject Is the recommendation in the
TA applicable to organization?Does Locala comply with the NICE
Technology Appraisal?TA425 Dasatinib, nilotinib and high-dose imatinib for treating
imatinib-resistant or intolerant chronic myeloid leukaemia
No
TA424 Pertuzumab for the neoadjuvant treatment of HER2- positive breast cancer
No
TA423 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
No
TA422 Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
No
TA421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
No
TA420 Ticagrelor for preventing atherothrombotic events after myocardial infarction
Yes Yes
TA419 Apremilast for treating moderate to severe plaque psoriasis
No
TA418 Dapagliflozin in triple therapy for treating type 2 diabetes
Yes Yes
TA417 Nivolumab for previously treated advanced renal cell carcinoma
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
No
TA415 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
No
TA414 Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
No
TA413 Elbasvir-grazoprevir for treating chronic hepatitis C No
TA412 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
No
TA411 Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
No
TA410 Talimogene laherparepvec for treating unresectable metastatic melanoma
No
TA409 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
No
TA408 Pegaspargase for treating acute lymphoblastic leukaemia
No
TA407 Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
No
TA406 Crizotinib for untreated anaplastic lymphoma kinase- positive advanced non-small-cell lung cancer
No
TA405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA401 Bosutinib for previously treated chronic myeloid leukaemia
No
TA404 Prostate cancer (advanced, hormone dependent) - degarelix depot
No
TA402 Pemetrexed maintenance treatment for non- squamous non-small-cell lung cancer after pemetrexed and cisplatin
No
TA403 Lung cancer (non-small cell, metastatic) - ramucirumab (after platinum chemotherapy)
No
TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma
No
TA398 Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
No
TA399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
No
TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
No
TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
No
TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
No
TA397 Belimumab for treating active autoantibody-positive systemic lupus erythematosus
No
TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa
No
TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA390 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Yes Yes
TA391 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
No
TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
No
TA388 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Yes Yes
TA387 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
No
TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
No
TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
No
TA382 Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)
No
TA377 Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
No
TA379 Nintedanib for treating idiopathic pulmonary fibrosis No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA381 Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
No
TA380 Panobinostat for treating multiple myeloma after at least 2 previous treatments
No
TA376 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
No
TA378 Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
No
NICE TAs 2014-15TA Subject Is the recommendation in the
TA applicable to organization?Does Locala comply with the NICE
Technology Appraisal?TA373 Abatacept, adalimumab, etanercept and tocilizumab
for treating juvenile idiopathic arthritis No
TA372 Apremilast for treating active psoriatic arthritis No
TA370 Bortezomib for previously untreated mantle cell lymphoma
No
TA369 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
No
TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA371 Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
No
TA368 Apremilast for treating moderate to severe plaque psoriasis
No
TA364 Daclatasvir for treating chronic hepatitis C No
TA363 Ledipasvir–sofosbuvir for treating chronic hepatitis C No
TA365 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
No
TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab
No
TA367 Vortioxetine for treating major depressive episodes No
TA539 Idelalisib for treating chronic lymphocytic leukaemia No
TA360 Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer
No
TA362 Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)
No
TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
No
TA361 Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal)
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA358 Tolvaptan for treating autosomal dominant polycystic kidney disease
No
TA356 Ruxolitinib for treating polycythaemia vera (terminated appraisal)
No
TA355 Atrial fibrillation (non-valvular) - edoxaban tosylate [ID624]
Yes Yes
TA354 Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]
No
TA353 Bevacizumab for treating relapsed, platinum - resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)
No
TA352 Crohn's disease (moderate to severe) - vedolizumab [ID690]
No
TA345 Constipation (opioid-induced) - naloxegol [ID674] Yes Yes
TA349 Macular oedema (diabetic) - dexamethasone intravitreal implant [ID653]
No
TA350 Psoriasis (plaque, moderate to severe) – secukinumab [ID718]
Yes Yes
TA348 Organ rejection (liver transplantation, prevention) - everolimus [ID559]
No
TA346 Macular oedema (diabetic) - aflibercept [ID717] No
TA347 Lung cancer (non-small cell) - nintedanib [ID438] No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA344 Leukaemia (chronic lymphocytic, previously untreated) - ofatumumab
No
TA343 Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line)
No
TA341 Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) – apixaban
Yes Yes
TA313 Psoriatic arthritis (active) - ustekinumab (Rapid Rev No
TA349 Urticaria (chronic spontaneous, previously treated) - omalizumab Jun 15
No
TA342 Ulcerative colitis (moderate to severely active) - vedolizumab Jun 15
No
TA338 Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (Mar15)
No
TA337 Rifaximin for preventing episodes of overt hepatic encephalopathy (Mar15)
No
TA336 Empagliflozin in combination therapy for treating type 2 diabetes (Mar15)
Yes Yes
TA335 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (Mar15)
Yes Yes
TA334 Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (Feb15)
No
TA333 Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (Feb15)
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA332 Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone- relapsed prostate cancer (Feb15)
No
TA331 Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (Feb15)
No
TA330 Sofosbuvir for treating chronic hepatitis C (Feb15) No
TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (Feb15)
No
HST1 Eculizumab for treating atypical haemolytic uraemic syndrome (Jan15)
No
TA328 Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (Dec14)
No
TA327 Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (Dec14)
No
TA326 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (Nov14)
No
TA325 Nalmefene for reducing alcohol consumption in people with alcohol dependence (Nov14)
Yes Yes
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA324 Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (Nov14)
No
TA323 Erythropoiesis-stimula ting agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (Nov14)
Yes Yes
TA321 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (Oct14)
No
TA322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (Sep14)
No
TA320 Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (Aug14)
No
TA319 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (Jul14)
No
TA318 Lubiprostone for treating chronic idiopathic constipation (Jul14)
Yes Yes
TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes Jul14)
Yes Yes
TA316 Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (Jul14)
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA315 Canagliflozin in combination therapy for treating type 2 diabetes (TA315) (Jun14)
Yes Yes
TA314 Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120) (Jun14)
Yes Yes
TA313 Psoriatic arthritis (active) - ustekinumab May 14) No
TA312 Multiple sclerosis (relapsing-remitting) - alemtuzumab (May14)
No
TA311 Multiple myeloma - bortezomib (induction therapy) (Apr14)
No
TA310 Lung cancer (non small cell, EGFR mutation positive) - afatinib (Apr14)
No
TA309 Lung cancer (non small cell, non squamous) - pemetrexed (Apr14)
No No
NICE TAs 2013-14
TA Subject Is the recommendation in the TA applicable to organization?
Does Locala comply with the NICE Technology Appraisal?
TA308 Vasculitis (anti-neutrophil cytoplasmic antibody- associated) - rituximab (with glucocorticoids)
No
TA307 Colorectal cancer (metastatic) - aflibercept No
TA306 Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy Feb'14)
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA305 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection ( Feb'14)
No
TA304 Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44) (Feb'14)
No
TA303 Multiple sclerosis (relapsing) - teriflunomide (Jan'14)
No
TA302 Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (Nov'13)
No
TA301 Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (Nov'13)
Yes Yes
TA300 Hepatitis C (children and young people) - peginterferon alfa and ribavirin (Nov'13)
No
TA299 Bosutinib for previously treated chronic myeloid leukaemia (Nov'13)
No
TA298 Choroidal neovascularisation (pathological myopia) - ranibizumab (Nov'13)
No
TA297 Vitreomacular traction - ocriplasmin (October '13) No
TA296 Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib (September '13)
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA295 Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (August '13)
No
TA294 Macular degeneration (wet age-related) aflibercept (July '13)
No
TA293 Thrombocytopenic purpura - eltrombopag (July '13) No
TA292 Bipolar disorder (children) - aripiprazole (July '13) Yes Yes
TA291 Gout (tophaceous, severe debilitating, chronic) - pegloticase (June '13)
No
TA290 Overactive bladder - mirabegron (June '13) Yes Yes
TA289 Myelofibrosis (splenomegaly, symptoms) - ruxolitinib (June'13)
No
TA288 Type 2 diabetes - Dapagliflozin combination therapy (June '13)
Yes Yes
TA287 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (June '13)
Yes Yes
TA286 Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (May'13)
No
TA285 Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum- sensitive advanced ovarian cancer (May'13)
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (May'13)
No
TA283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (May'13)
No
TA282 Pirfenidone for treating idiopathic pulmonary fibrosis (Apr'13)
No
TA281 Gout - canakinumab (terminated appraisal) (Apr'13)
No
TA280 Abatacept for treating rheumatoid arthritis after the failure of conventional disease- modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234) (Apr'13)
No
TA279 Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures (Apr'13)
No
TA278 Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201) (Apr'13)
No
NICE TAs 2012-13
TA Subject Is the recommendation in the TA applicable to organization?
Does Locala comply with the NICE Technology Appraisal?
TA277 Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)
No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA276 Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
No
TA275 Stroke and systemic embolism (prevention, non- valvular atrial fibrillation) - apixaban
Yes Yes
TA274 Macular oedema (diabetic) - ranibizumab No
TA273 Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)
No
TA272 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
No
TA271 Diabetic macular oedema - fluocinolone acetonide intravitreal implant
No
TA270 Leukaemia (acute myeloid ) - decitabine (terminated appraisal)
No
TA269 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
No
TA268 Melanoma (stage III or IV) - ipilimumab No
TA267 Chronic heart failure - ivabradine No
TA266 Cystic fibrosis - mannitol dry powder for inhalation No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA265 Bone metastases from solid tumours - denosumab Yes Yes
TA264 Stroke (acute, ischaemic) - alteplase No
TA263 Bevacizumab in combination with capecitabine for the first- line treatment of metastatic breast cancer
No
TA262 Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal)
No
TA261 Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban
Yes Yes
TA260 Migraine (chronic) - botulinum toxin type A No
TA259 Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy)
Yes Yes
TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
No
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)
No
TA256 Atrial fibrillation (stroke prevention) - rivaroxaban Yes Yes
TA255 Prostate cancer - cabazitaxel Yes Yes
TA254 Multiple sclerosis (relapsing- remitting) - fingolimod No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA253 Hepatitis C (genotype 1) - boceprevir No
TA252 Hepatitis C (genotype 1) - telaprevir No
TA251 Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
No
TA250 Breast cancer (advanced) - eribulin No
NICE TAs 2011-12
TA Subject Is the recommendation in the TA applicable to organization?
Does Locala comply with the NICE Technology Appraisal?
TA249 Atrial fibrillation - dabigatran etexilate Yes Yes
TA248 Diabetes (type 2) - exenatide (prolonged release) Yes Yes
TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198) No
TA246 Venom anaphylaxis - immunotherapy pharmalgen Yes Yes
TA245 Venous thromboembolism - apixaban (hip and knee surgery)
Yes Yes
TA244 Chronic obstructive pulmonary disease - roflumilast No
TA243 Follicular lymphoma - rituximab (review) No
Locala Community PartnershipsReport of Compliance with NICE Technology Appraisals
TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
No
TA241 Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
No
TA240 Colorectal cancer (metastatic) - panitumumab (terminated appraisal)
No
TA239 Breast cancer (metastatic) - fulvestrant No
TA238 Arthritis (juvenile idiopathic, systemic) - tocilizumab No
TA237 Macular oedema (diabetic) - ranibizumab No
TA236 Acute coronary syndromes - ticagrelor Yes
TA235 Osteosarcoma - mifamurtide No
